Pharmacokinetic and pharmacodynamic study of S-1 and its effects in patients with the digestive organ cancer with reference to genetic polymorphism and activity of CYP2A6 [cytochrome P450 2A6 enzyme] and DPD [dihydropyrimidine dehydrogenase]
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Gastrointestinal cancer
- Focus Pharmacokinetics
- 23 Oct 2005 New trial record.